Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $1.19 Million Position in Surmodics, Inc. (NASDAQ:SRDX)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 165.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,000 shares of the company's stock after purchasing an additional 18,692 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS owned about 0.21% of Surmodics worth $1,188,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Quest Partners LLC grew its holdings in Surmodics by 107,100.0% during the third quarter. Quest Partners LLC now owns 1,072 shares of the company's stock worth $42,000 after acquiring an additional 1,071 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Surmodics by 1.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 116,311 shares of the company's stock worth $4,511,000 after acquiring an additional 1,491 shares during the last quarter. Algert Global LLC grew its position in shares of Surmodics by 29.9% in the third quarter. Algert Global LLC now owns 17,820 shares of the company's stock valued at $691,000 after purchasing an additional 4,098 shares in the last quarter. ClearAlpha Technologies LP grew its holdings in Surmodics by 99.2% in the 3rd quarter. ClearAlpha Technologies LP now owns 50,152 shares of the company's stock valued at $1,945,000 after buying an additional 24,979 shares in the last quarter. Finally, Murchinson Ltd. acquired a new stake in Surmodics during the third quarter worth about $2,133,000. Hedge funds and other institutional investors own 96.63% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Lake Street Capital upgraded shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price target on the stock in a research note on Friday, March 7th. Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a report on Thursday, January 30th. Finally, StockNews.com began coverage on Surmodics in a research report on Monday, February 3rd. They issued a "hold" rating for the company. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $50.00.

Surmodics Trading Up 0.5 %

Surmodics stock traded up $0.14 during midday trading on Friday, reaching $30.75. The stock had a trading volume of 43,450 shares, compared to its average volume of 279,338. The stock's 50-day simple moving average is $32.87 and its 200 day simple moving average is $36.75. The stock has a market capitalization of $439.60 million, a PE ratio of -30.45 and a beta of 1.19. Surmodics, Inc. has a twelve month low of $25.17 and a twelve month high of $42.44. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. Analysts expect that Surmodics, Inc. will post 0.2 EPS for the current year.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).